CURE

FDA Approves Guardant360 CDx Diagnostic For Some With Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E …

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration

Guardant Health (GH) is back in focus after the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer and the company announced a ...

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...
USA Today

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / ...
Seeking Alpha

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatment ESR1 mutations are present in 40% of HR+, HER2- advanced breast cancers “This FDA ...